BioPorto A/S reports strong growth in US sales of NGAL tests and progress in strategic plan

From GlobeNewswire: 2024-08-15 02:37:00

BioPorto A/S announces strong growth in US sales of NGAL tests and progress in executing its strategic plan for the second quarter and first six months of fiscal 2024. Double-digit growth across all product lines, new US standing order, and ongoing clinical studies for FDA submission of ProNephro AKI™. Financial highlights show increased revenue and cash reserves. Guidance for 2024 remains on track with total revenue target and adjusted EBITDA loss range. Management to host online and physical investor meetings. BioPorto focuses on empowering early detection of Acute Kidney Injury with NGAL biomarkers to improve patient outcomes. Shares listed on Nasdaq Copenhagen.



Read more at GlobeNewswire:: BioPorto Announces Interim Results and Business Update for